Health
Breakthrough Drug Offers Hope, Doubles Pancreatic Cancer Survival
A groundbreaking new drug, elraglusib, shows remarkable promise in treating pancreatic cancer, potentially doubling survival rates and significantly cutting the risk of death. A Phase 2 clinical trial revealed that patients receiving elraglusib alongside chemotherapy lived longer and had better one and two-year survival outcomes. This development offers a beacon of hope for patients facing one of ...
